We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 04. | 장 마감 후 (AMC) | $6.18 | — | — | $1.11B | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $-1.52 | — | — | $897.8M | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $5.63 | — | — | $2.98B |
Consensus PT $253.21 · 19 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 28. | Barclays | — | 의견 유지 | Overweight → Overweight | — | Barclays: Overweight |
| 2026. 05. 22. | Bernstein | — | 커버리지 개시 | — → Market Perform | — | Bernstein: Market Perform |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $2.35 | — | — | $1.93B | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 358,634 | $67.8B | 0.12% | — | 신규 편입 |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 175,000 | $29.75B | 0.05% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Stored first · Google News · Yahoo Finance (English)
Jazz Pharmaceuticals PLC (JAZZ): CBD-Based Epidiolex Drug Sales Up 15% - Yahoo Finance
Jazz Pharmaceuticals PLC (JAZZ): CBD-Based Epidiolex Drug Sales Up 15% Yahoo Finance
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After A Strong Multi Period Share Price Run - simplywall.st
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After A Strong Multi Period Share Price Run simplywall.st
Jazz Pharmaceuticals plc (JAZZ) seeks votes on director elections, share‑issuance powers - Stock Titan
Jazz Pharmaceuticals plc (JAZZ) seeks votes on director elections, share‑issuance powers Stock Titan
Jazz Pharmaceuticals (JAZZ) director Anne O’Riordan will not seek re-election after 2026 - Stock Titan
Jazz Pharmaceuticals (JAZZ) director Anne O’Riordan will not seek re-election after 2026 Stock Titan